drugset / Trial / NCT04552288
Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether the study drug benralizumab is a safe treatment that can reduce the skin side effects caused by cancer treatment by reducing the level of eosinophils in your blood. Reducing the skin side effects of your cancer treatment may improve quality of life and allow participants to continue to receive their usual cancer treatment.
Timeline
- Start
- 2020-09-16
- Primary completion
- 2024-07-19
- Completion
- 2026-05-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benralizumab | Monoclonal antibody | 30 mg | Subcutaneous |